{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:32:03Z","timestamp":1768894323215,"version":"3.49.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":952,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1002\/rth2.12327","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T05:41:39Z","timestamp":1585978899000},"page":"532-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cancer\u2010associated venous thromboembolism: Treatment and prevention with rivaroxaban"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1741","authenticated-orcid":false,"given":"Rupert","family":"Bauersachs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes Y.Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-903X","authenticated-orcid":false,"given":"Gerald","family":"Soff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/rth2.12327_bb0010","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1160\/TH16-06-0486","article-title":"Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE","volume":"116","author":"Bach","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0015","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1002\/rth2.12327_bb0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.disamonth.2016.03.003","article-title":"Cancer\u2010associated thrombosis","volume":"62","author":"Fuentes","year":"2016","journal-title":"Dis Mon"},{"key":"10.1002\/rth2.12327_bb0025","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"10.1002\/rth2.12327_bb0030","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12957-015-0592-8","article-title":"Venous thromboembolism in cancer patients: an underestimated major health problem","volume":"13","author":"Khalil","year":"2015","journal-title":"World J Surg Oncol"},{"key":"10.1002\/rth2.12327_bb0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high\u2010risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12327_bb0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12327_bb0045","unstructured":"Fadoi Foundation. Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. (PRO\u2010LAPSII). 2018. [Accessed 17 July 2019]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03055026"},{"key":"10.1002\/rth2.12327_bb0050","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer\u2010associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12327_bb0055","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral Factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT\u2010D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1002\/rth2.12327_bb0060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0065","doi-asserted-by":"crossref","first-page":"v724","DOI":"10.1093\/annonc\/mdz265.020","article-title":"Patient\u2010reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer","volume":"30","author":"Cohen","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1002\/rth2.12327_bb0070","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0075","unstructured":"Assistance Publique \u2013 H\u00f4pitaux de Paris. Cancer associated thrombosis, a pilot treatment study using rivaroxaban (CASTA\u2010DIVA). 2018. [Accessed 12 August 2019]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02746185"},{"key":"10.1002\/rth2.12327_bb0080","unstructured":"AIO\u2010Studien\u2010gGmbH. Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. 2018 [accessed 12 August 2019]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02583191"},{"issue":"5","key":"10.1002\/rth2.12327_bb0085","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12327_bb0090","unstructured":"National Comprehensive Cancer Network. Cancer\u2010associated venous thromboembolic disease, version 1.2019. Plymouth Meeting, PA, USA: National Comprehensive Cancer Network, Inc. 2019. [Accessed 12 August 2019] Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf"},{"key":"10.1002\/rth2.12327_bb0095","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines","volume":"6","author":"Mandal\u00e0","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1002\/rth2.12327_bb0100","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1002\/rth2.12327_bb0105","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1002\/rth2.12327_bb0110","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0115","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer\u2010associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low\u2010molecular\u2010weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12327_bb0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180\u2010day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1002\/rth2.12327_bb0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep\u2010vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59\u20137939): the ODIXa\u2010DVT (Oral Direct Factor Xa Inhibitor BAY 59\u20137939 in patients with acute symptomatic Deep\u2010Vein Thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/rth2.12327_bb0135","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/rth2.12327_bb0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1002\/rth2.12327_bb0145","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11239-017-1478-0","article-title":"Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1002\/rth2.12327_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2013.11.001","article-title":"Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants","volume":"28","author":"Wharin","year":"2014","journal-title":"Blood Rev"},{"key":"10.1002\/rth2.12327_bb0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: Are treatment guidelines for cancer\u2010associated venous thromboembolism being followed?","volume":"145","author":"Khorana","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12327_bb0160","first-page":"15539","article-title":"Anticoagulant treatment patterns for cancer\u2010associated thrombosis in a commercial insurance population","volume":"136","author":"Khorana","year":"2017","journal-title":"Circulation"},{"key":"10.1002\/rth2.12327_bb0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer\u2010associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11239-015-1313-4","article-title":"Guidance for the prevention and treatment of cancer\u2010associated venous thromboembolism","volume":"41","author":"Khorana","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1002\/rth2.12327_bb0175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.thromres.2018.08.023","article-title":"Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta\u2010analysis","volume":"170","author":"Vedovati","year":"2018","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12327_bb0180","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer\u2010associated thrombosis: a systematic review and meta\u2010analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12327_bb0185","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"10.1002\/rth2.12327_bb0190","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1002\/rth2.12327_bb0195","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","article-title":"Drug interactions in oncology: how common are they?","volume":"20","author":"Riechelmann","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1002\/rth2.12327_bb0200","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-019-6314-9","article-title":"Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population\u2010based 12 year follow up study","volume":"19","author":"Jakobsen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1002\/rth2.12327_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jamacardio.2016.0280","article-title":"Risk of malignant cancer among women with new\u2010onset atrial fibrillation","volume":"1","author":"Conen","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1002\/rth2.12327_bb0210","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/rth2.12327_bb0215","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1002\/rth2.12327_bb0220","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/rth2.12327_bb0225","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","article-title":"Usefulness of CHADS2 and CHA2DS2\u2010VASc scores for stroke prediction in patients with cancer and atrial fibrillation","volume":"120","author":"Patell","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1002\/rth2.12327_bb0230","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cam4.1054","article-title":"Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population\u2010based cohort study","volume":"6","author":"Ording","year":"2017","journal-title":"Cancer Med"},{"key":"10.1002\/rth2.12327_bb0235","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non\u2010valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH","author":"Delluc","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0240","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12327_bb0245","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"},{"key":"10.1002\/rth2.12327_bb0250","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12327_bb0255","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo\u2010controlled, double\u2010blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1002\/rth2.12327_bb0260","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.thromres.2018.01.018","article-title":"Apixaban for the prevention of venous thromboembolism in high\u2010risk ambulatory cancer patients receiving chemotherapy: rational and design of the AVERT trial","volume":"164","author":"Kimpton","year":"2018","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12327_bb0265","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1160\/TH17-03-0171","article-title":"Rivaroxaban for preventing venous thromboembolism in high\u2010risk ambulatory patients with cancer: rationale and design of the CASSINI trial. Rationale and design of the CASSINI trial","volume":"117","author":"Khorana","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0270","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0275","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1160\/TH16-12-0946","article-title":"Clinical impact of major bleeding in patients with venous thromboembolism treated with Factor Xa inhibitors or vitamin K antagonists","volume":"117","author":"Bleker","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0280","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer\u2010associated venous thromboembolism: results from the Hokusai VTE Cancer study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0285","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14656566.2018.1496238","article-title":"Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance","volume":"19","author":"Imberti","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1002\/rth2.12327_bb0290","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1160\/TH17-03-0193","article-title":"Apixaban and dalteparin in active malignancy associated venous thromboembolism","volume":"117","author":"McBane","year":"2017","journal-title":"The ADAM VTE trial. Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0295","unstructured":"University Hospital Akershus. Apixaban as treatment of venous thrombosis in patients with cancer: the CAP study. 2018. [Accessed 17 July 2019] Available from https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02581176"},{"key":"10.1002\/rth2.12327_bb0300","unstructured":"The University of Hong Kong. A study of dabigatran etexilate as primary treatment of malignancy associated venous thromboembolism. 2017. [Accessed 17 July 2019] Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03240120"},{"key":"10.1002\/rth2.12327_bb0305","unstructured":"Alliance Foundation Trials LLC, Patient\u2010Centered Outcomes Research Institute. Direct oral anticoagulants versus LMWH +\/\u2010 warfarin for VTE in cancer (CANVAS). 2018. [Accessed 16 December 2019] Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02744092"},{"key":"10.1002\/rth2.12327_bb0310","doi-asserted-by":"crossref","first-page":"E58E61","DOI":"10.1002\/ajh.25361","article-title":"The risk of recurrent VTE and major bleeding in a commercially\u2010insured population of cancer patients treated with anticoagulation","volume":"94","author":"Khorana","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12327_bb0315","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13074","article-title":"Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer\u2010associated venous thromboembolism","author":"Simmons","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1002\/rth2.12327_bb0320","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11239-016-1429-1","article-title":"Safe and effective use of rivaroxaban for treatment of cancer\u2010associated venous thromboembolic disease: a prospective cohort study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1002\/rth2.12327_bb0325","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/rth2.12215","article-title":"Rivaroxaban treatment of cancer\u2010associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience","volume":"3","author":"Soff","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0330","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1055\/s-0037-1603924","article-title":"Subgroup analysis of patients with cancer in XALIA: a noninterventional study of rivaroxaban versus standard anticoagulation for VTE","volume":"1","author":"Ageno","year":"2017","journal-title":"TH Open"},{"key":"10.1002\/rth2.12327_bb0335","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ajh.25059","article-title":"Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer","volume":"93","author":"Streiff","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1002\/rth2.12327_bb0340","doi-asserted-by":"crossref","first-page":"491","DOI":"10.6004\/jnccn.2018.7008","article-title":"Effectiveness and safety of rivaroxaban in patients with cancer\u2010associated venous thrombosis","volume":"16","author":"Kohn","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1002\/rth2.12327_bb0345","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ajh.25604","article-title":"Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer\u2010associated venous thromboembolism","volume":"94","author":"Wysokinski","year":"2019","journal-title":"Am J Hematol"},{"issue":"Supplement_1","key":"10.1002\/rth2.12327_bb0350","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2019-128095","article-title":"Patient preferences regarding anticoagulation therapy in patients with cancer having a VTE event \u2010 a Discrete Choice Experiment in the COSIMO study","volume":"34","author":"Picker","year":"2019","journal-title":"Blood"},{"key":"10.1002\/rth2.12327_bb0355","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta\u2010analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"key":"10.1002\/rth2.12327_bb0365","first-page":"57","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer","volume":"117","author":"Cohen","year":"2017","journal-title":"A population\u2010based cohort study. Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0370","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low\u2010molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO\u2010004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1002\/rth2.12327_bb0375","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1002\/rth2.12327_bb0380","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma \u2010 choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1002\/rth2.12327_bb0385","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2017.01.009","article-title":"Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial","volume":"151","author":"Khorana","year":"2017","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12327_bb0390","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy\u2010associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1002\/rth2.12327_bb0395","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1182\/blood-2018-99-116224","article-title":"The rate of venous thromboembolism in cancer patients varies by Khorana risk category","volume":"132","author":"Khorana","year":"2018","journal-title":"Blood"},{"key":"10.1002\/rth2.12327_bb0400","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta\u2010analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12327_bb0405","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/S2352-3026(18)30067-X","article-title":"Simplicity versus complexity: an existential dilemma as risk tools evolve","volume":"5","author":"Khorana","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1002\/rth2.12327_bb0410","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer\u2010associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1002\/rth2.12327_bb0415","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"van Es","year":"2017","journal-title":"Haematologica"},{"key":"10.1002\/rth2.12327_bb0420","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2017-05-787929","article-title":"When can we stop anticoagulation in patients with cancer\u2010associated thrombosis?","volume":"130","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"10.1002\/rth2.12327_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19830","article-title":"A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost\u2010effective length of Anticoagulation with Low\u2010molecular\u2010weight heparin In the treatment of Cancer\u2010Associated Thrombosis (ALICAT)","volume":"vii\u2013xxiii","author":"Noble","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1002\/rth2.12327_bb0430","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study","volume":"157","author":"Jara\u2010Palomares","year":"2017","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12327_bb0435","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post\u2010hoc analysis of the Hokusai\u2010VTE Cancer study","author":"Di Nisio","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0440","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jth.13606","article-title":"Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study","volume":"15","author":"Tardy","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12327_bb0445","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/SLA.0000000000000340","article-title":"A randomized study on 1\u2010week versus 4\u2010week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer","volume":"259","author":"Vedovati","year":"2014","journal-title":"Ann Surg"},{"key":"10.1002\/rth2.12327_bb0450","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/0269216305pm1008oa","article-title":"Is long\u2010term low\u2010molecular\u2010weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism?","volume":"19","author":"Noble","year":"2005","journal-title":"A qualitative study. Palliat Med"},{"key":"10.1002\/rth2.12327_bb0455","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2016.06.005","article-title":"Low\u2010molecular\u2010weight heparins for cancer\u2010associated thrombosis: adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409\u2010patient prospective observational study","volume":"144","author":"Cajfinger","year":"2016","journal-title":"Thromb Res"},{"key":"10.1002\/rth2.12327_bb0460","first-page":"453","article-title":"Cancer\u2010associated thrombosis, low\u2010molecular\u2010weight heparin, and the patient experience: a qualitative study","volume":"8","author":"Seaman","year":"2014","journal-title":"Patient preference and adherence"},{"key":"10.1002\/rth2.12327_bb0465","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-018-0176-2","article-title":"COSIMO \u2010 patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non\u2010interventional study","volume":"16","author":"Cohen","year":"2018","journal-title":"Thromb J"},{"key":"10.1002\/rth2.12327_bb0470","unstructured":"Hart Wilcox. Frontline2: Fundamental research in oncology and thrombosis. 2018. [Accessed 17 July 2019] Available from http:\/\/frontline2.tri\u2010london.ac.uk\/"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frth2.12327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12327","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922020040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922020040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:20:26Z","timestamp":1762863626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922020040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S2475037922020040"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12327","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer\u2010associated venous thromboembolism: Treatment and prevention with rivaroxaban","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}